GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

Agentic AI refers to AI systems that add layers of reason and autonomy. They act as largely independent agents that are ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...